Blinatumoab公司
医学
CD19
肿瘤科
内科学
免疫疗法
临床试验
免疫学
抗原
癌症
作者
Franco Locatelli,Bijal Shah,Tracy Thomas,Kelly Velasco,Babatunde Adedokun,Ibrahim Aldoss,Lia Gore,Dieter Hoelzer,Renato Bassan,Jae H. Park,Nicolas Boissel,Hagop M. Kantarjian
标识
DOI:10.1080/10428194.2023.2232496
摘要
There are inconsistencies in the reporting of CD19 antigen status following treatment with CD19-targeted therapies. A majority of evidence comes from studies reporting small sample sizes. In this review, we systematically summarize published studies that have reported rates of CD19-negative relapse after treatment with either blinatumomab or CD19-directed CAR T-cell therapy and report the rates of CD19-negative relapse when evaluated in a standardized way across trials. CD19-negative relapse appears to occur more commonly in relapses following CAR T-cell therapy compared with blinatumomab, whether proportions are calculated among all treated patients (8.7% vs 4.5%) or among patients who relapse (30% vs 22.5%). The median (range) duration of follow-up was 29.3 (17.4-50.8) and 20.4 (6.9-49.0) months for publications on blinatumomab (n = 10) and CAR T-cell therapies (n = 23), respectively. There is a need for standardized reporting of CD19 antigen status in the setting of relapse following novel immunotherapies to inform clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI